CooperCompanies stock holds its line as fiscal 2025 metrics stay central

CooperCompanies (ISIN US21664P1039) stock remains anchored by fiscal 2025 results, with revenue of $4.06 billion, net income of $404.7 million, and diluted EPS of $8.39 for the year ended 31 October 2025. Those figures define the current fundamental base even as the share price context must be read through the latest verified market data available to this article.

FY2025 revenue reached $4.06 billion

For fiscal 2025, CooperCompanies reported revenue of $4.06 billion, up from $3.91 billion in fiscal 2024, which implies year-on-year growth of about 3.8%. Net income rose to $404.7 million in fiscal 2025 from $394.1 million a year earlier, while diluted EPS increased to $8.39 from $8.02.

The revenue mix still matters. CooperVision generated $3.47 billion in fiscal 2025 revenue, while CooperSurgical contributed $585.7 million, giving investors a clear split between the contact-lens business and the medical-device segment.

EPS rose to $8.39

The earnings line is the cleaner comparison point. Diluted EPS of $8.39 in fiscal 2025 was 4.6% above the prior-year $8.02, and that improvement came even as net income advanced by only 2.7% year on year, showing how share count and mix can shape per-share progress.

Margin discipline also showed up in the year-end numbers. Gross profit reached $2.74 billion in fiscal 2025 versus $2.66 billion in fiscal 2024, while operating income came in at $587.7 million compared with $594.3 million a year earlier.

Product mix drives the story

CooperVision remains the company’s core product engine, with the fiscal 2025 segment delivering $3.47 billion of revenue. That is more than five times the $585.7 million reported by CooperSurgical, so the contact-lens franchise continues to dominate the group profile.

For readers tracking operating scale, the division split is useful because it shows where growth and margin leverage matter most. Fiscal 2025 revenue of $4.06 billion is still supported primarily by recurring lens demand, not by a single one-off contract or a short-cycle order spike.

Market valuation backdrop

The stock remains tied to these 2025 numbers until a newer market print or interim report changes the picture. In that sense, the latest verified anchor here is the fiscal year ended 31 October 2025, not a headline-driven one-day move.

For investors and traders, the key comparison is straightforward: revenue increased by $152.0 million year on year, EPS improved by $0.37, and net income added $10.6 million. Those are the figures that set the baseline for any reassessment of CooperCompanies stock.

CooperVision remains central

CooperVision, the group’s larger segment, is the product line that carries the main revenue load and gives CooperCompanies its most important recurring-sales profile. Fiscal 2025 revenue of $3.47 billion versus CooperSurgical revenue of $585.7 million shows how concentrated the business mix remains in vision care.

Closing price context

CooperCompanies stock is best read against fiscal 2025 rather than a fresh trading quote in this article, with revenue at $4.06 billion and diluted EPS at $8.39 serving as the most recent verified operating markers. The latest dated figures also show 3.8% revenue growth and a 4.6% EPS increase year on year.